Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex John

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Clinical Trials (London, England)|November 11, 2005
Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisalHoward Mann, Alex John London, Jeffrey Mann
JPRAS Open|February 23, 2026
Morel-Lavallée lesion-An overview and case reportJephin Alex John, Mathias Tremp, Thomas R Henkel
The American Journal of Bioethics : AJOB|March 6, 2014
The ethics of advertising for health care servicesYael Schenker, Robert M Arnold, Alex John London
Augmentative and Alternative Communication (Baltimore, Md. : 1985)|July 12, 2017
Provision of powered communication aids in the United KingdomSimon Judge, Pam Enderby, Sarah Creer, et al.
Cell Stem Cell|August 9, 2015
Patient-Funded Trials: Opportunity or Liability?Danielle Marie Wenner, Jonathan Kimmelman, Alex John London
BMJ Case Reports|December 1, 2021
Inferior gluteal pain with sitting, unrelated to ischial bursitisChad Mears, Renuka Rudra, Alex John, et al.
Kennedy Institute of Ethics Journal|April 8, 2024
Varieties of Community Uncertainty and Clinical EquipoiseAlex John London, Patrick Bodilly Kane, Jonathan Kimmelman
Plos Medicine|April 6, 2012
Improving ethical review of research involving incentives for health promotionAlex John London, David A Borasky, Anant Bhan, et al.
Pakistan Journal of Pharmaceutical Sciences|July 7, 2019
Antagonistic activity of an epibiotic Bacillus strain SG3 from Gorgonian coral, Junceella juncea (Pallas, 1766)Alex John Thangapaul, M Mark Praveevn, Chellaram Chinnachamy
International Journal of Language & Communication Disorders|April 27, 2016
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the needSarah Creer, Pamela Enderby, Simon Judge, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Clinical Trials (London, England)|November 11, 2005
Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisalHoward Mann, Alex John London, Jeffrey Mann
JPRAS Open|February 23, 2026
Morel-Lavallée lesion-An overview and case reportJephin Alex John, Mathias Tremp, Thomas R Henkel
The American Journal of Bioethics : AJOB|March 6, 2014
The ethics of advertising for health care servicesYael Schenker, Robert M Arnold, Alex John London
Augmentative and Alternative Communication (Baltimore, Md. : 1985)|July 12, 2017
Provision of powered communication aids in the United KingdomSimon Judge, Pam Enderby, Sarah Creer, et al.
Cell Stem Cell|August 9, 2015
Patient-Funded Trials: Opportunity or Liability?Danielle Marie Wenner, Jonathan Kimmelman, Alex John London
BMJ Case Reports|December 1, 2021
Inferior gluteal pain with sitting, unrelated to ischial bursitisChad Mears, Renuka Rudra, Alex John, et al.
Kennedy Institute of Ethics Journal|April 8, 2024
Varieties of Community Uncertainty and Clinical EquipoiseAlex John London, Patrick Bodilly Kane, Jonathan Kimmelman
Plos Medicine|April 6, 2012
Improving ethical review of research involving incentives for health promotionAlex John London, David A Borasky, Anant Bhan, et al.
Pakistan Journal of Pharmaceutical Sciences|July 7, 2019
Antagonistic activity of an epibiotic Bacillus strain SG3 from Gorgonian coral, Junceella juncea (Pallas, 1766)Alex John Thangapaul, M Mark Praveevn, Chellaram Chinnachamy
International Journal of Language & Communication Disorders|April 27, 2016
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the needSarah Creer, Pamela Enderby, Simon Judge, et al.
Pageof 9